Authors
Muhammad Auwal Saliu, Mansur Dabai Salisu, Rabiatu Bako Suleiman, Wei Liang, Abdulrahman Ibrahim, Abubakar Dalhatu, Adeleye O Adeshakin, Isaac Adeyemi Babarinde, Guizhong Zhang, Dehong Yan, Xudong Liu, Maoxuan Liu, Xiaochun Wan
Published in
Molecular therapy. Oncology. Volume 34. Issue 4. Pages 201349. Dec 17, 2026. Epub Sep 23, 2026.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal solid tumor with limited responsiveness to chimeric antigen receptor (CAR) T cell therapy. A major challenge is antigen heterogeneity, which allows antigen-low or antigen-negative tumor cells to escape immune pressure. Here, we identified mesothelin (MSLN) and NKG2D ligands (NKG2DLs) as a complementary antigen pair in PDAC, showing frequent but discordant expression in clinical specimens. Based on this, we generated single-target, tandem, and dual CAR constructs against MSLN and/or NKG2DLs and compared their antitumor activity. Among them, an asymmetric split-costimulatory dual-CAR, MSLN.BBz/NKG2D.28, showed the best overall performance. MSLN.BBz/NKG2D.28 CAR-T cells efficiently eliminated single-positive, double-positive, and mixed-antigen tumor populations, sustained serial killing, produced higher effector cytokines, and preserved a less exhausted, more memory-like phenotype in vitro. In vivo, MSLN.BBz/NKG2D.28 CAR-T achieved stronger tumor control, greater intratumoral accumulation, improved persistence, and prolonged survival in pancreatic tumor models, including those mimicking antigen heterogeneity. Transcriptomic, biochemical, and pharmacologic analyses further identified IL-2-STAT5 signaling as an important pathway supporting the enhanced fitness and antitumor activity of this construct. Together, these findings show that dual targeting alone is insufficient; the arrangement of receptor inputs and costimulatory signals strongly influences therapeutic output. This study identifies MSLN.BBz/NKG2D.28 as a promising dual-CAR strategy for PDAC.
PMID:
43036814
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0